drugset / Trial / NCT04607200
AGEN2034 & AGEN1884 in Patients With Recurrent, Inoperable Angiosarcoma
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This Phase 2, open-label study is designed to examine the efficacy and safety of single-agent AGEN2034 and combination AGEN2034 + AGEN1884 in patients with recurrent, inoperable or metastatic Angiosarcoma (AS).
Timeline
- Start
- 2021-02
- Primary completion
- 2021-09-13
- Completion
- 2021-09-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Balstilimab | Monoclonal antibody | 3 mg/kg | Intravenous |
| Subject | Zalifrelimab | Monoclonal antibody | 1 mg/kg | Intravenous |